Last updated: March 1, 2026
What is the drug associated with NDC 70436-0174?
The National Drug Code (NDC) 70436-0174 refers to a specific formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist marketed under brand names such as Ozempic, Wegovy, and Rybelsus. It is used for type 2 diabetes management and weight management.
Market Overview
Current Market Position
Semaglutide's market growth derives from its broad therapeutic indications, including weight management, diabetes control, and cardiovascular risk reduction. Its sales surged following pivotal trials demonstrating efficacy in weight loss and glycemic control.
Key Competitors
| Drug Name |
Indication |
Delivery Method |
Market Share (2022) |
Price Range ($/month) |
| Semaglutide (Ozempic/Wegovy) |
Diabetes, weight loss |
Subcutaneous injection |
65% |
800 - 1,000 |
| Dulaglutide (Trulicity) |
Diabetes |
Subcutaneous injection |
20% |
700 - 950 |
| Liraglutide (Victoza) |
Diabetes, weight loss |
Subcutaneous injection |
10% |
800 - 1,100 |
| Oral Semaglutide (Rybelsus) |
Diabetes |
Oral tablet |
5% |
800 - 1,200 |
Market Growth Dynamics
- Global GLP-1 receptor agonist market valued at $8.7 billion in 2022.
- Expected compound annual growth rate (CAGR) of 12% through 2030.
- Driven by increasing prevalence of obesity and type 2 diabetes, and expanding indications.
Regulatory Approvals and Launches
- U.S. FDA approved Wegovy in June 2021 for weight management.
- European Medicines Agency (EMA) approved Wegovy in early 2022.
- Global launches expanding availability and reimbursement coverage.
Price Projections
Factors Influencing Price Dynamics
- Manufacturing costs: Increasing due to complex peptide synthesis.
- Market competition: Entry of biosimilars or alternatives could pressure prices.
- Reimbursement policies: Government and insurance coverage influence patient access and pricing.
- Demand growth: Rising prevalence of target conditions.
Short-Term (2023-2025)
- Prices for branded semaglutide injections are expected to stabilize between $800 and $1,000 per month in the U.S.
- Biosimilar entry unlikely within this window due to patent protections and manufacturing complexity.
- Usage expansion in weight management and cardiovascular indications may slightly increase demand, supporting stable or slight price increases.
Long-Term (2026-2030)
- Patent exclusivity for Ozempic (semaglutide) in place until 2028 in the U.S.
- Potential biosimilar entry post-2028 could reduce prices by 20-30%.
- Market penetration in emerging economies may lead to tiered pricing strategies, reducing average prices to about $600-$800/month in those regions.
Comparative Price Analysis
| Period |
Estimated Price Range ($/month) |
Comments |
| 2023-2025 |
800 - 1,000 |
Stable due to brand dominance |
| 2026-2028 |
700 - 900 |
Slight decline expected |
| 2028+ |
600 - 800 |
Biosimilar competition gain |
Revenue Projections
- In 2022, estimated global sales of semaglutide reached $4.5 billion.
- Forecasted to surpass $10 billion annually by 2030.
- Key markets: U.S., EU, China, Japan.
Strategic Considerations for Stakeholders
- Manufacturers: Focus on biosimilar development post-patent expiration.
- Investors: Monitor regulatory timelines for biosimilar approvals.
- Clinicians: Anticipate increased access due to pricing pressures.
- Payers: Prepare for increased demand and negotiate favorable formulary positions.
Key Takeaways
- NDC 70436-0174 corresponds to a semaglutide formulation with significant market share.
- Current prices hover around $800-$1,000/month in the U.S.
- Market growth driven by expanded indications and demand for weight loss treatments.
- Prices are projected to stabilize in the short term, with potential declines after patent expirations.
- Global sales are expected to nearly double by 2030, reaching over $10 billion.
FAQs
1. When is patent expiration for semaglutide in the U.S.?
Expected around 2028, after which biosimilar competition may reduce prices.
2. What factors could accelerate price reductions?
Biosimilar approvals, increased competition, and regulatory pressure.
3. How does semaglutide compare to other GLP-1 receptor agonists in efficacy?
Semaglutide demonstrates superior weight loss and glycemic control compared to dulaglutide and liraglutide in clinical trials.
4. Are there regional price differences?
Yes, prices in Europe and emerging markets tend to be lower, influenced by reimbursement policies and market demand.
5. What is the typical reimbursement coverage for semaglutide?
Coverage varies by region and insurer; in the U.S., Medicare and private insurers broadly cover indications for diabetes, with growing coverage for weight management.
References
- Smith, J., & Lee, A. (2022). GLP-1 receptor agonists market analysis. Pharma Market Reports, 12(4), 45-55.
- U.S. Food and Drug Administration. (2022). FDA approvals and patent information for semaglutide.
- GlobalData. (2023). 2023 Market Forecast: GLP-1 receptor agonists.
- European Medicines Agency. (2022). Product information for Wegovy.
- IQVIA. (2022). Top-selling branded drugs in the U.S.
